Landmark analyses for PFS in clinical remission after ASCT (MCL Younger trial) or end of induction (MCL Elderly trial). For each landmark time point, patients in follow-up at the landmark are included and stratified according to MRD status in PB in the 6-month period preceding the landmark.³⁵